FDA Approves Jardiance to Treat Diabetes (粮食与药物管理局批准Jardiance治疗糖尿病)
The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Jardiance – Block the reabsorption of glucose (blood sugar) by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levels
Jardiance – NOT suitable to treat people with type 1 diabetes; those who have increased ketones in their blood or urine (diabetic ketoacidosis); and in those with severe renal impairment, end stage renal disease, or in patients on dialysis.
Jardiance – Can cause dehydration, leading to a drop in blood pressure (hypotension) that can result in dizziness and/or fainting and a decline in renal function.
Side effects - Urinary tract infections and female genital infections.
Here is the Original Article, courtesy of FDA.